Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS)

References

• Farne HA, Wilson A, Milan S, et al. Anti-IL-5 therapies for asthma. Cochrane Database Syst Rev. 2022 Jul;7(7). doi: 10.1002/14651858.CD010834.pub4
   PubMedGoogle Scholar
• Takatsu K, Takaki S, Hitoshi Y. Interleukin-5 and its receptor system: implications in the immune system and inflammation. Adv Immunol. 1994;57:145–190. doi:10.1016/s0065-2776(08)60673-2
   PubMed Web of Science ®Google Scholar
• Takatsu K. Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(8):463–485. doi:10.2183/pjab.87.463
   PubMed Web of Science ®Google Scholar
• Nagase H, Ueki S, Fujieda S. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. Allergol Int. 2020 Apr;69(2):178–186. doi: 10.1016/j.alit.2020.02.002
   PubMed Web of Science ®Google Scholar
• Adachi T, Alam R. The mechanism of IL-5 signal transduction. Am J Physiol. 1998 Sep;275(3):C623–33. doi: 10.1152/ajpcell.1998.275.3.C623
   PubMed Web of Science ®Google Scholar
• Dhillon SS, Toor NK, Ramos-Nino ME, et al. Mepolizumab as a potential protective factor of COVID-19 mortality: a case report of chronic bronchitis and asthma in an elderly patient. Am J Case Rep. 2022 Dec;23:e938450. doi: 10.12659/AJCR.938450
   PubMed Web of Science ®Google Scholar
• Lombardi C, Gani F, Berti A, et al. Asthma and COVID-19: a dangerous liaison? Asthma Res Pract. 2021 Jul;7(1):9. doi: 10.1186/s40733-021-00075-z
   PubMedGoogle Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2016 Oct;388(10056):2128–2141. doi: 10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang Y, Zhang M, et al. Monoclonal antibodies targeting IL-5 or IL-5Rα in eosinophilic chronic obstructive pulmonary disease: a systematic review and meta-analysis. Front Pharmacol. 2021;12:754268. doi: 10.3389/fphar.2021.754268
   PubMed Web of Science ®Google Scholar
• Walsh GM. Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update. Expert Opin Biol Ther. 2020 Oct;20(10):1237–1244. doi: 10.1080/14712598.2020.1782381
   PubMed Web of Science ®Google Scholar
• Esnault S, Johansson MW, Mathur SK. Eosinophils, beyond IL-5. Cells. 2021 Oct;10(10):2615. doi: 10.3390/cells10102615
   PubMed Web of Science ®Google Scholar
• Shomali W, Gotlib J. World Health OrgaNization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022 Jan;97(1):129–148. doi: 10.1002/ajh.26352
   PubMed Web of Science ®Google Scholar
• Koike H, Nishi R, Furukawa S, et al. In vivo visualization of eosinophil secretion in eosinophilic granulomatosis with polyangiitis: an ultrastructural study. Allergol Int. 2022 Jul;71(3):373–382. doi: 10.1016/j.alit.2022.02.009
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet (London, England). 2012 Aug;380(9842):651–659. doi: 10.1016/S0140-6736(12)60988-X
   PubMed Web of Science ®Google Scholar
• Manka LA, Guntur VP, Denson JL, et al. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Ann Allergy Asthma Immunol. 2021 Jun;126(6):696–701.e1. doi: 10.1016/j.anai.2021.01.035
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022 Apr;149(4):1309–1317.e12. doi: 10.1016/j.jaci.2021.08.030
   PubMed Web of Science ®Google Scholar
• Parnes JR, Molfino NA, Colice G, et al. Targeting TSLP in asthma. J Asthma Allergy. 2022;15:749–765. doi: 10.2147/JAA.S275039
   PubMed Web of Science ®Google Scholar
• Pertzov B, Unterman A, Shtraichman O, et al. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. J Asthma. 2021 Jan;58(1):79–84. doi: 10.1080/02770903.2019.1658208
   PubMed Web of Science ®Google Scholar
• Yıldız R, Demirel YS, Mungan VD, et al. Incidence and clinical course of COVID-19 in patients using omalizumab for chronic spontaneous urticaria and/or severe allergic asthma and using mepolizumab for severe eosinophilic asthma: a single center real life experience. Tuberk Toraks. 2022 Sep;70(3):231–241. doi: 10.5578/tt.20229702
   PubMed Web of Science ®Google Scholar
• Aksu K, Yesilkaya S, Topel M, et al. COVID-19 in a patient with severe asthma using mepolizumab. Allergy Asthma Proc. 2021 Mar;42(2):e55–e57. doi: 10.2500/aap.2021.42.200125
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA Adverse event reporting System. Int J Med Sci. 2013;10(7):796–803. doi: 10.7150/ijms.6048
   PubMed Web of Science ®Google Scholar
• FDA. FDA Adverse Event Reporting System (FAERS) 2021. Available from: https://www.fda.gov/drugs/surveillance/questions-andanswers-fdas-adverse-event-reporting-system-faers.
   Google Scholar
• Peng J, Wang H, Liu Z, et al. Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database. Front Pharmacol. 2022;13:1017391. doi: 10.3389/fphar.2022.1017391
   PubMed Web of Science ®Google Scholar
• Chen J, Wen Y, Chu X, et al. Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors. Front Pharmacol. 2022;13:944342. doi: 10.3389/fphar.2022.944342
   PubMed Web of Science ®Google Scholar
• Jiang JJ, Zhao B, Li J. Does eltrombopag lead to thrombotic events? A pharmacovigilance study of the FDA Adverse Event Reporting System. J Clin Pharm Ther. 2022 Oct;47(10):1556–1562. doi: 10.1111/jcpt.13701
   PubMed Web of Science ®Google Scholar
• Guo M, Shu Y, Chen G, et al. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for niraparib. Sci Rep. 2022 Nov;12(1):20601. doi: 10.1038/s41598-022-23726-4
   PubMed Web of Science ®Google Scholar
• Hauben M. A brief primer on automated signal detection. Ann Pharmacother. 2003 Jul;37(7–8):1117–1123. doi: 10.1345/aph.1C515
   PubMed Web of Science ®Google Scholar
• Hauben M, Madigan D, Gerrits CM, et al. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. 2005 Sep;4(5):929–948. doi: 10.1517/14740338.4.5.929
   PubMedGoogle Scholar
• Norén GN, Bate A, Orre R, et al. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med. 2006 Nov;25(21):3740–3757. doi: 10.1002/sim.2473
   PubMed Web of Science ®Google Scholar
• Sundström A, Hallberg P. Data mining in pharmacovigilance–detecting the unexpected: the role of index of suspicion of the reporter. Drug Saf. 2009;32(5):419–427. doi: 10.2165/00002018-200932050-00005
   PubMed Web of Science ®Google Scholar
• Szarfman A, Machado SG, O’Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA’s spontaneous reports database. Drug Saf. 2002;25(6):381–392. doi: 10.2165/00002018-200225060-00001
   PubMed Web of Science ®Google Scholar
• Cazzola M, Ora J, Cavalli F, et al. An Overview of the safety and Efficacy of monoclonal antibodies for the chronic obstructive pulmonary disease. Biol: Targets Ther. 2021;15:363–374. doi: 10.2147/BTT.S295409
   PubMed Web of Science ®Google Scholar
• Shu Y, He X, Wu P, et al. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA Adverse Event Reporting System. Front Public Health. 2022;10:996179. doi: 10.3389/fpubh.2022.996179
   PubMed Web of Science ®Google Scholar
• Magnan A, Bourdin A, Prazma CM, et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy. 2016 Sep;71(9):1335–1344. doi: 10.1111/all.12914
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep;371(13):1189–1197. doi: 10.1056/NEJMoa1403291
   PubMed Web of Science ®Google Scholar
• Chowdhury NU, Guntur VP, Newcomb DC, et al. Sex and gender in asthma. Eur Respir Rev. 2021 Dec;30(162):210067. doi: 10.1183/16000617.0067-2021
   PubMed Web of Science ®Google Scholar
• Calzetta L, Ritondo BL, Matera MG, et al. Targeting IL-5 pathway against airway hyperresponsiveness: a comparison between benralizumab and mepolizumab. Br J Pharmacol. 2020 Oct;177(20):4750–4765. doi: 10.1111/bph.15240
   PubMed Web of Science ®Google Scholar
• Harish A, Schwartz SA. Targeted anti-IL-5 therapies and future therapeutics for hypereosinophilic syndrome and rare eosinophilic conditions. Clin Rev Allergy Immunol. 2020 Oct;59(2):231–247. doi: 10.1007/s12016-019-08775-4
   PubMed Web of Science ®Google Scholar
• Ueno M, Miyagawa I, Aritomi T, et al. Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study. Arthritis Res Ther. 2022 Jun;24(1):159. doi: 10.1186/s13075-022-02845-3
   PubMed Web of Science ®Google Scholar
• Carr TF, Berdnikovs S, Simon HU, et al. Eosinophilic bioactivities in severe asthma. World Allergy Organ J. 2016;9:21. doi: 10.1186/s40413-016-0112-5
   PubMed Web of Science ®Google Scholar
• Aksu K, Demir Ş, Topel M, et al. COVID-19 in patients with severe asthma using biological agents. Tuberk Toraks. 2021 Sep;69(3):433–436. doi: 10.5578/tt.20219721
   PubMed Web of Science ®Google Scholar
• Akenroye A, Lassiter G, Jackson JW, et al. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a bayesian network meta-analysis. J Allergy Clin Immunol. 2022 Nov;150(5):1097–1105.e12. doi: 10.1016/j.jaci.2022.05.024
   PubMed Web of Science ®Google Scholar
• Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 May;75(5):1023–1042. doi: 10.1111/all.14221
   PubMed Web of Science ®Google Scholar
• Kavanagh J, Jackson DJ, Kent BD. Sleep and asthma. Curr Opin Pulm Med. 2018 Nov;24(6):569–573. doi: 10.1097/MCP.0000000000000526
   PubMed Web of Science ®Google Scholar
• Zhao B, Shen J, Zhao J, et al. Do sodium–glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real-world study. J Diabetes Investig. 2021 Aug;12(8):1400–1407. doi: 10.1111/jdi.13481
   PubMed Web of Science ®Google Scholar